Walleye Capital
MLTX icon

Walleye Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

Walleye Capital’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.6K Sell
2,700
-3,700
-58% -$67.1K ﹤0.01% 4168
2026
Q1 		$119K Sell
6,400
-400
-6% -$6.63K ﹤0.01% 3599
2025
Q4 		$89.6K Buy
+6,800
New +$80.2K ﹤0.01% 3911
2024
Q4 		– Sell
-3,200
Closed -$161K – 5273
2024
Q3 		$161K Buy
+3,200
New +$150K ﹤0.01% 4146

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Walleye Capital's MLTX Position: Q2 2026 in Review

Walleye Capital reduced its MoonLake Immunotherapeutics (MLTX) stake by 23% in Q2 2026, selling an estimated $1.33M and leaving 246,869 shares worth $4.81M. The position accounts for 0.02% of the portfolio, ranked #852.

Walleye Capital first reported a position in MLTX in Q3 2023 and has held it in 8 quarters since. The position peaked at $11.3M in Q4 2024. 172 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Walleye Capital held 246,869 shares of MoonLake Immunotherapeutics worth $4.81M as of Q2 2026.
  • Walleye Capital sold 73,603 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $1.33M.
  • MoonLake Immunotherapeutics made up 0.02% of Walleye Capital's portfolio in Q2 2026, its #852 holding.
  • Walleye Capital first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 8 quarters since.
  • Walleye Capital's MoonLake Immunotherapeutics position peaked at $11.3M in Q4 2024.
  • 172 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.